Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again

View original at nasdaq.com
The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again Key Points Netlist owns patents that form the foundation of memory chips, resulting in legal wins against Micron and Samsung that can produce meaningful licensing royalties in the future…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The jury verdicts from Micron and Samsung alone are worth almost Netlist's entire market cap.

    60% confidence
  • Motley Fool Stock Advisor's total average return is 993%, compared to 208% for the S&P 500.

    60% confidence
  • Netlist can issue an injunction that bans the sale of memory chips in the U.S., ruining backlogs in the process.

    60% confidence
  • If Netlist continues to deliver high sequential growth and scores big legal wins resulting in licensing royalties, its stock should soar.

    60% confidence
  • Netlist has silently become a major part of the AI bottleneck due to its patents.

    60% confidence
  • Netlist gets far more negotiating power as the AI boom continues, which can result in better licensing terms.

    60% confidence
  • Netlist was not among the Motley Fool Stock Advisor's 10 best stocks for investors to buy now as of May 22, 2026.

    60% confidence
  • The longer Micron and Samsung drag their feet in the patent cases, the more consequential the damages may become.

    60% confidence
  • Consecutive quarters of high sequential growth can be an indicator of a breakout AI stock, following the pattern of Sandisk and Micron which delivered multiple quarters of high sequential growth before most investors noticed the opportunity.

    60% confidence
  • Netlist remains well positioned to capitalize on AI memory technologies — DDR5 and HBM — through our products and IP assets.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
The 1 Tech Stock I Keep Adding To on Red Days -- and Why I'll Do It Again — Source | Via News | ViaNews EU